ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2861

Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA

Ashley Visser 1, Marie Feser 2, Chelsie Fleischer 3, Laura Lenis-Charry 1, Justin August 1, Elizabeth Bemis 4, Jill Norris 5, V. Michael Holers 6, Kevin Deane 2 and M. Kristen Demoruelle7, 1University of Colorado Denver, Aurora, 2University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora, CO, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO USA, Aurora, 4University of Colorado Denver, School of Public Health, Aurora, CO USA, Aurora, 5Colorado School of Public Health, Aurora, 6University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver, 7University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Aurora

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), pathogenesis and lung, rheumatoid arthritis, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 13, 2019

Title: 6W012: RA – Etiology & Pathogenesis II (2858–2863)

Session Type: ACR Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Systemic autoimmunity associated with RA precedes the onset of inflammatory arthritis (IA) by several years. In particular, the presence of systemic anti-cyclic citrullinated peptide (CCP) antibody is a strong predictor of developing classified RA in the future. However, the mechanisms involved in the transition from systemic anti-CCP to IA classifiable as RA are unknown. Our group has previously identified the local generation of anti-CCP and rheumatoid factor (RF) antibodies in the sputum of subjects at-risk for RA, including those with serum anti-CCP positivity. It has also been demonstrated that a portion of serum anti-CCP+ individuals have chronic lung disease preceding joint disease in RA. Herein, we aimed to determine the relationship between lung-related factors and the transition from systemic autoimmunity to classified RA.

Methods: In 49 subjects who were serum anti-CCP-IgG+ without IA, we collected baseline induced sputum using hypertonic saline. Baseline serum and sputum supernatant were tested by ELISA for CCP-IgG (CCP3, Inova), RF-IgM (Inova) and RF-IgA (Inova). Sputum antibody positivity was defined as a level above the 95th percentile in values determined from a separate cohort of 80 serum anti-CCP negative controls without IA. All subjects were followed longitudinally up to 3 years. Incident RA was determined by 2010 ACR/EULAR classification criteria. Chi-square and Wilcoxon rank-sum testing was used to compare factors associated with incident RA.

Results: Eight (16%) of 49 subjects developed classified RA during follow-up (median time to RA 14 months). Factors associated with developing RA are listed in the Table. Similar to previous data, we found that higher serum anti-CCP-IgG level (p=0.05) and serum RF positivity (p< 0.01) were associated with developing RA. In addition, we also found multiple lung-related factors associated with developing classified RA, including a self-reported history of any chronic lung disease (OR=7.6, 95% CI 1.2-48.4), sputum positivity for anti-CCP-IgG or 2 RF isotypes (RF-IgA and RF-IgM) (OR=12.0, 95% CI 2.2-66.3) and a trend toward an association with current smoking (OR=13.3, 95% CI 1.0-170.6). Of note, both current smokers who developed classified RA had sputum autoantibody positivity. When considering these lung factors in aggregate, incident RA was 15 times more likely in subjects with sputum RA-related antibodies or chronic lung disease (OR=14.6, 95% CI 14.4-87.7).

Conclusion: In a cohort of serum anti-CCP+ subjects, we found that lung-related factors at baseline, including sputum anti-CCP, sputum RF isotypes and a history of chronic lung disease, were associated with developing classified RA within a short duration of follow-up (< 3 years). These data support that biological pathways in the lung may be important in transitions from systemic autoimmunity to arthritis in RA. Based on our findings, it will be particularly important to understand whether the generation of anti-CCP and RF in the lung is a mediating factor that links smoking and RA. In addition, 2 of 8 subjects who developed RA did not have sputum autoantibodies or chronic lung disease, which could suggest other mucosal site involvement in their transitions to RA.


table


Disclosure: A. Visser, None; M. Feser, None; C. Fleischer, None; L. Lenis-Charry, None; J. August, None; E. Bemis, None; J. Norris, BMS, 5, Celgene, 5, Janssen R&D, 2, Pfizer, 2; V. Holers, AdMIRx, 1, 2, 4, 5, 6, Alexion, 7, BMS, 5, Bristol-Myers Squibb, 5, Celgene, 5, Janssen R&D, 2, 5, Pfizer, 2; K. Deane, Bristol-Myers Squibb, 5, Inova, 9, Janssen, 2, 5, Janssen R&D, 2, Microdrop, 5, Pfizer, 2; M. Demoruelle, Pfizer, 2.

To cite this abstract in AMA style:

Visser A, Feser M, Fleischer C, Lenis-Charry L, August J, Bemis E, Norris J, Holers V, Deane K, Demoruelle M. Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/lung-related-factors-are-associated-with-transitions-from-systemic-anti-ccp-antibody-positivity-to-classified-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lung-related-factors-are-associated-with-transitions-from-systemic-anti-ccp-antibody-positivity-to-classified-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology